News + Resources
Life Sciences M&A: A Vital Catalyst for Investment and Innovation
With more than 80% of life sciences companies operating without a profit, external investment—including from venture capital (VC)—is often critical to bringing a new treatment or cure to market. As macroeconomic headwinds have made investors increasingly cautious about investing in early-stage companies, mergers and acquisitions (M&A) play a crucial role in sustaining innovation across the American life sciences ecosystem.
New PULSE Resource: Life Sciences Innovations Advanced by M&A
For decades, mergers and acquisitions (M&A) have fueled the development and delivery of breakthrough treatments for complex diseases with a high unmet need. A new resource from the Partnership for the U.S. Life Science Ecosystem (PULSE) spotlights this unique and...
New PULSE Resources: M&A Fuels Innovation, Competition in America’s Life Sciences Industry
New resources from the Partnership for the U.S. Life Science Ecosystem (PULSE) highlight the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. Life sciences M&A represents a critical pathway for companies of all...
Maryland Daily Record Op-Ed: “Misguided Antitrust Policies Jeopardize Maryland Life Sciences Industry”
In a recent op-ed for The Maryland Daily Record, Kelly Schulz, CEO of PULSE Partner Maryland Tech Council, discusses discusses how federal policy against mergers and acquisitions (M&A) could undermine Maryland’s status as an innovation leader in the life sciences.
Innovations Advanced by M&A: A Novel Treatment for Atopic Dermatitis
For many early-stage life sciences companies, mergers and acquisitions (M&A) represent a critical path. M&A helps companies unlock the complementary resources and expertise that help advance a new therapy from the lab to patients at scale. For example, Dermira’s acquisition by Eli Lilly & Co. helped bring Ebglyss, a novel monoclonal antibody treatment, to patients living with moderate-to-severe atopic dermatitis (AD).
By the Numbers: Early-Stage Life Sciences Companies Rely on Balanced M&A Policies to Fuel Innovation
Competition policies that support pro-competitive mergers and acquisitions (M&A) are critical to fueling innovation, competition and growth in America’s life sciences industry. Importantly, M&A has a quantifiable impact for the ecosystem and for the thousands of companies bringing new treatments and cures to market.
The Future of Antitrust: Key Takeaways from the 2024 National Lawyers Convention
During a recent panel discussion at the 2024 National Lawyers Convention, leading antitrust experts underscored the impact of recent policy shifts from the Federal Trade Commission (FTC) and Department of Justice (DOJ). In America’s life sciences ecosystem, the FTC and DOJ’s policies have risked stifling pro-competitive mergers and acquisitions (M&A), which help companies of all sizes bring new treatments to patients.
PULSE and 35+ Other Stakeholders Urge Congress to Overturn FTC’s New HSR Rule
This week, PULSE joined over 35 leading business and industry stakeholders in calling for leaders of the House Judiciary Committee to overturn the Biden Administration’s Hart-Scott-Rodino (HSR) premerger notification rule changes.
Pro-Innovation M&A Fuels Growth, Innovation in America’s Life Sciences Industry
It’s critical that competition policies reflect the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. Policies that support pro-competitive life sciences M&A can help drive growth, incentivize investment and, most importantly, advance new medical innovations to patients.
NJBIZ Op-Ed: “Federal Anti-M&A Policy Could Undermine New Jersey’s Leadership in the Life Sciences”
In a recent op-ed for NJBIZ, Debbie Hart, President and CEO of PULSE Partner BioNJ, discusses how federal policy against mergers and acquisitions (M&A) could undermine New Jersey’s leadership in the life sciences.